Table of Contents

Chapter 1: Head and Neck Tumors

Chapter 2: Thyroid and Parathyroid Cancers

Chapter 3: Non-Small-Cell Lung Cancer

Chapter 4: Small-Cell Lung Cancer, Mesothelioma, and Thymoma

Chapter 5: Breast Cancer Overview

Chapter 6: Stages 0 and I breast cancer

Chapter 7: Stage II breast cancer

Chapter 8: Stages III and IV breast cancer

Chapter 9: Esophageal cancer

Chapter 10: Gastric cancer

Chapter 11: Pancreatic, neuroendocrine GI, and adrenal cancers

Chapter 12: Liver, gallbladder, and biliary tract cancers

Chapter 13: Colon, rectal, and anal cancers

Chapter 14: Prostate cancer

Chapter 15: Testicular cancer

Chapter 16: Urothelial and kidney cancers

Chapter 17: Cervical cancer

Chapter 18: Uterine corpus tumors

Chapter 19: Ovarian cancer

Chapter 20: Melanoma and other skin cancers

Chapter 21: Bone sarcomas

Chapter 22: Soft-tissue sarcomas

Chapter 23: Primary and metastatic brain tumors

Chapter 24: AIDS-related malignancies

Chapter 25: Carcinoma of an unknown primary site

Chapter 26: Hodgkin lymphoma

Chapter 27: Non-Hodgkin lymphoma

Chapter 28: Multiple myeloma and other plasma cell dyscrasias

Chapter 29: Acute leukemias

Chapter 30: Chronic myeloid leukemia

Chapter 31: Chronic lymphocytic leukemia

Chapter 32: Myelodysplastic syndromes

Chapter 33: Hematopoietic cell transplantation

Chapter 34: Pain management

Chapter 35: Management of nausea and vomiting

Chapter 36: Depression, anxiety, and delirium

Chapter 37: Fatigue and dyspnea

Chapter 38: Anorexia and cachexia

Chapter 39: Oncologic emergencies and paraneoplastic syndromes

Chapter 40: Infectious complications

Chapter 41: Fluid complications

Color atlas The ABCDEs of moles and melanomas

Color atlas 2: Skin lesions

Color atlas 3: Dermatologic toxicities associated with targeted therapies

Appendix 1: Response Evaluation Criteria and Performance Scales

Appendix 2: Cancer Information on the Internet

Appendix 3: Cancer Drugs and Indications Newly Approved by the US Food and Drug Administration

Appendix 4: Chemotherapeutic Agents Their Uses, Dosages, and Toxicites

News & News Analysis

Duration of tamoxifen use influences cancer risk in opposite breast
Oncology NEWS International,  October 15, 2009
Low-risk tumors exhibit high proliferation index
Oncology NEWS International,  October 15, 2009
Bayer Taps New CEO
Oncology NEWS International,  October 15, 2009
Adjuvant Rx yields minor benefit in less aggressive colon cancer
Oncology NEWS International,  October 15, 2009
Low expression of MSH2 protein predicts survival in NSCLC
Oncology NEWS International,  September 29, 2009
Most Popular Articles

 

Order Your Copy!